2C-D

Discovery

2C-D was first synthesized by Beng T. Ho and colleagues in 1970.^[4] Alexander Shulgin began self-testing it at sub-threshold doses as early as 1964 and reached active doses by 1974–1975.^[4]

Clinical and cultural significance

Under the designation LE-25, German psychiatrist Hanscarl Leuner used 2C-D as an adjunct in psycholytic psychotherapy — not as a primary agent, but to extend and modulate the effects of co-administered substances.^[5][9] Shulgin documented it as entry #23 in PiHKAL,^[5] characterizing it as "pharmacological tofu" — a compound whose primary value was potentiating other substances.

Prohibition

2C-D remained unscheduled in the United States for over four decades. The Synthetic Drug Abuse Prevention Act of 2012 explicitly placed it in Schedule I.^[6] The United Kingdom had already classified it as Class A under a 2002 amendment covering all PiHKAL phenethylamines.^[4]

Structural class

2C-D belongs to the 2C family of phenethylamines — compounds built on a 2,5-dimethoxyphenethylamine backbone with a variable group at the 4-position.^[10]

The 4-position carries a methyl group — the smallest in the 2C series — which is why 2C-D is less potent than relatives like 2C-B (4-bromo) and 2C-I (4-iodo).^[11] It is the structural phenethylamine counterpart of DOM, with the molecular formula C₁₁H₁₇NO₂ (195.26 g/mol).

Molecular properties

Mechanism of action

2C-D activates serotonin receptors in the prefrontal cortex,^[11][3] increasing excitatory signaling in a way that produces the perceptual and cognitive shifts of psychedelic states.^[2] It is classified as a weak agonist at these receptors,^[1] making it less potent than 2C-B, 2C-I, and 2C-E. Studies in animals confirm it engages the same serotonergic pathway as other classical psychedelics.^[12][13]

Pharmacokinetics

No pharmacokinetic data specific to 2C-D have been published.^[7] The 2C series broadly is thought to be metabolized by removal of methoxy groups from the ring, primarily through MAO-A,^[7] with possible involvement of liver enzymes.^[14] Effects begin within 15–45 minutes of oral ingestion and last 4–6 hours^[5] — figures from Shulgin's self-experiments, not clinical studies.

Where it acts

2C-D activates serotonin receptors concentrated in the prefrontal cortex,^[2][3] increasing excitatory signaling and disrupting the brain's normal filtering of sensory and cognitive input. Because 2C-D binds weakly, these disruptions are proportionally milder than those produced by more potent psychedelics like LSD or psilocybin.

Why it matters

One theory proposes that psychedelics increase the disorder of brain activity, expanding the range of accessible conscious states.citation needed A related model suggests they loosen the brain's reliance on prior expectations, allowing more cognitive flexibility.citation needed 2C-D's reputation as a mild potentiator — amplifying other substances without strongly defining the experience — may represent a partial version of this effect at standard doses.

Toxicity

No lethal dose data exist for 2C-D, and no deaths attributed specifically to it alone appear in the published literature.^[7] A clinical toxicology review of the 2C series documented five deaths across the class — involving 2C-E and 2C-I, not 2C-D.^[7]

For the 2C series as a class, documented acute adverse presentations include^[7]:

• Hallucinations, agitation, aggression, and dysphoria
• Elevated blood pressure and rapid heart rate
• Seizures
• Dangerously elevated body temperature
• Excited delirium (documented in fatalities involving other 2C compounds)
• Serotonin toxicity

2C-D's monoamine oxidase inhibitory activity adds a further risk: blocking this enzyme raises monoamine levels, amplifying cardiovascular stress and serotonin toxicity — especially in combination with other substances.^[8]

Psychological risks

No controlled data on 2C-D-specific psychological risk exist. Class-level risks for serotonergic psychedelics include acute anxiety, panic reactions, and psychological destabilization in people with personal or family histories of psychotic disorders.

The relatively mild profile at standard doses suggests lower acute psychological risk than more potent psychedelics, though the poorly documented high-dose range carries unknown risk. inferred

Tolerance and dependence

Tolerance to serotonergic psychedelics develops rapidly after a single use. In mouse studies, tolerance to the related compound DOI developed within 24 hours of a single dose, with progressive tolerance over 4 days,^[15] driven by downregulation in the frontal cortex.^[15]

Cross-tolerance with LSD was confirmed in the same study,^[15] supporting the expectation that all serotonin receptor psychedelics — including 2C-D — share it. No evidence of physical dependence, withdrawal, or compulsive use exists for 2C-D or any 2C-series compound.^[7]

Drug interactions

Tramadol is a particularly dangerous combination. It blocks the SERT, raising synaptic serotonin;^[16] combined with 2C-D's receptor agonism and MAO inhibition,^[8] these pathways converge. Tramadol fatalities in combination with MAOIs are documented,^[17] and tramadol additionally lowers the seizure threshold.

Classical MAOIs produce dual MAO inhibition alongside direct serotonin receptor agonism^[8][17] — a high-risk combination for serotonin toxicity. 2C-series compounds have been documented in serotonin syndrome case reports when combined with serotonergic agents.^[18]

Contraindications

No published contraindications specific to 2C-D exist. The following are inferred from its pharmacological class and MAO inhibitory propertiesinferred:

• Personal or family history of psychotic disorders — serotonin receptor activation can precipitate or worsen psychotic episodes in vulnerable individuals
• Bipolar disorder — psychedelic use carries risk of triggering manic episodes
• Heart conditions — elevated blood pressure and rapid heart rate are documented for the 2C-series class^[7] and may be clinically significant with pre-existing cardiovascular disease
• Concurrent MAOI use — dual MAO inhibition plus serotonin receptor agonism creates high risk for serotonin toxicity^[8]
• Concurrent serotonergic medication — SSRIs, SNRIs, tramadol, and other serotonin-raising agents create compounding risk
• Seizure disorders — seizures are documented among 2C-series adverse events^[7]
• Pregnancy — no reproductive toxicity data exist; standard precautionary contraindication applies

2C-D is a controlled substance in multiple jurisdictions, explicitly scheduled in the United States as Schedule I under the synthetic Drug Abuse Prevention Act of 2012.^[6] International scheduling varies, with most jurisdictions classifying 2C-D under blanket phenethylamine prohibitions or specific substance listings.

European Union country-by-country scheduling was not confirmed from primary legal databases. 2C-D is reported to be controlled across most EU member states, but specific schedules require verification. citation needed